Navigation Links
Vermillion Reports Results for Third Quarter 2011
Date:11/9/2011

cancer assets of Correlogic Systems. This acquisition allows us to gain access to their samples, IP and software, all of which could be additive to our ovarian program. Additionally, we save sample collection time and potentially gain further IP protection.

"We also advanced our pipeline this quarter with positive top-line results in our PAD intended use clinical study. This data was subsequently used to select a biomarker combination that identifies 80% of PAD patients missed by the conventional Framingham Risk Score. The availability of a simple blood test to reclassify patients missed by conventional risk assessment could greatly aid in the detection and management of this insidious disease.

"In the fourth quarter of 2011, we expect 4,000 to 4,300 OVA1 tests to be performed. This takes into consideration the impact of holidays, competition and limited coverage by the larger payers combined with the impact of direct patient bills."

Conference Call DetailsThe company will conduct a conference call to discuss its third quarter results later today at 8:30 a.m. Eastern time (Wednesday, November 9).

Interested parties may listen to the call by dialing (800) 686-5266 from the United States and Canada or +1 (303) 223-2680 internationally. The conference ID is 21542209.

A live webcast and replay will also be available via the Investor Relations section of the company's website at www.vermillion.com.

A telephone replay of the call will be available beginning approximately two hours after the call through November 23, 2011, and may be accessed by dialing (800) 633-8284 from the United States and Canada or +1 (402) 977-9140 internationally. The replay passcode is 21542209.  

About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of no
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
2. Vermillion Engages Liolios Group to Lead Investor Relations Program
3. Vermillion Enhances Management Team With A Key Addition
4. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
5. Vermillion Reports Financial Results for the First Quarter 2011
6. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
7. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
8. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
9. Vermillion Announces $21.8 Million Public Offering
10. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
11. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... the Morgan Stanley Healthcare conference on Tuesday, September ... Huennekens , president and chief executive officer, will ...
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... corporate and clinical activities at the company ... ongoing clinical trials and future clinical development ... Executive Officer Robert Hershberg , M.D., ...
(Date:9/2/2014)... Sept. 2, 2014  VentiRx Pharmaceuticals, Inc., ... the development and commercialization of novel Toll-like ... the U.S. Food and Drug Administration (FDA) ... investigation of motolimod (VTX-2337) when administered in ... the treatment of women with ovarian cancer ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... May 20, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) ... intermediates, and contract research and manufacturing services to customers ... the 2011 fiscal year (FY) ended March 31, 2011. ... in fiscal year 2011, Neuland delivered on our commitment ...
... Winner Medical Group Inc. (Nasdaq: WWIN ; ... medical dressings, medical disposables and non-woven fabric made from ... that its PurCotton Industrial Wipes was nominated one of ... Award™. The Company will compete with the ...
Cached Medicine Technology:Neuland Labs Reports Financial Results for Fiscal Year 2011 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 3Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 4
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced today ... makeup application device. Designed to improve and accelerate makeup ... palm of women’s hands to help them get flawless ... success lies in its patented technology. With a battery-operated ... pulses per minute, the device applies foundation evenly in ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of ... pleased to announce that it has released a special ... FY 2015 Hospital Inpatient Prospective Payment System (IPPS) final ... Medicaid Services. , “Hospitals are facing decreased Medicare reimbursements ... Besler, BESLER’s President and Chief Executive Officer. “We are ...
(Date:9/2/2014)... 02, 2014 At the world-famous Magic Castle ... the unique distinction of being the first and only female ... Lee is the first female magician to hold such a ... at the Magic Castle,” says Misty Lee. “Even since I ... the Magic Castle, I can fascinate guests in much the ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
Breaking Medicine News(10 mins):Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3
... are struggling with the health fallout caused by a lack ... Most women don,t need a survey to tell them a ... too sluggish to make it through the day with vigor. ... moms, empty-nesters or grandmothers, many -- if not most -- ...
... under 80, could ease expected worldwide shortfall of supplies , , ... called HBOC-201 proved safe and effective in a six-week Phase ... In all, 688 patients, ages 18 and older, who had ... (about one pint) or an equivalent one unit (65 grams) ...
... 20 The United States,has provided $50,000 in ... to assist people affected by the food,shortages in ... emerged in recent months because the flowering of ... rat infestations in,crop-growing areas. With funds provided by ...
... of,Agriculture is recommending that consumers who have purchased raw ... County, discard it immediately,due to the risk of Listeria ... milk is milk that has not been pasteurized or ... requires they obtain,permits and be inspected to reduce health ...
... Tenn., June 20 TeamHealth announced today,that Heidi S. ... counsel, reporting directly to the CEO. Ms. Allen is ... retire on July 31,2008, after nine years with TeamHealth., ... a member of TeamHealth,s senior,management team, working with all ...
... shows , , FRIDAY, June 20 (HealthDay News) -- Measles may ... world, but new research shows that it does not spread ... believed. , Mayo Clinic researchers, whose work was published ... of Clinical Investigation , reported that the measles virus instead ...
Cached Medicine News:Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:PA Agriculture Department Warns Consumers About Raw Milk Sold by York County Dairy 2Health News:TeamHealth Announces Appointment of Heidi Allen as Senior Vice President and General Counsel 2Health News:Measle's Spread Doesn't Depend on Airways 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: When high buckle is required. Overall length: 14.0 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
Medicine Products: